Table 3.

Selected results of high-dose chemotherapy and autologous stem cell transplantation in PTCL.

Study	N	Regimen	Response	OS	Comments
Retrospective series
Rodríguez et al. [33]	115	BEAM/BEAC/CVB/Cy + TBI	86% CR, 5% PR	56% at 5 y	PTCL
Yamazaki et al. [34]	11	CEM/HD-MTX	91% CR, 9% PR	72% at 3 y	No ALCL
Schetelig et al. [35]	14	Diverse	86% CR	60% at 5 y	AITL only
Kyriakou et al. [36]	146	Diverse	70% CR, 7% PR	59% at 4 y	AITL only
Prospective
Rodríguez et al. [37]	13	BEAM	65% CR, 4% PR	48% at 3 y	Subgroup analysis
Mercadel et al. [38]	41	High-dose CHOP/ESHAP	51% CR, 7% PR	29% at 4 y	41% received ASCR
D' Amore et al. [39]	77	BEAM	71% CR/PR	No data	75% received ASCR
Reimer et al. [40]	83	Cy/TBI	58% CR, 8% PR	48% at 3 y	66% received ASCR